Clinical trial
A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19
NCT03891420 is registered in ClinicalTrials.gov with BioCryst Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19
- Lead sponsor
- BioCryst Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- April 9, 2020
- Completion date
- April 30, 2021
- Enrollment
- 24 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.